Genomic Health, Inc. (NASDAQ:GHDX)

CAPS Rating: 4 out of 5

A life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Results 1 - 20 of 36 : 1 2 Next »

Recs

0
Member Avatar sikiliza (84.41) Submitted: 5/9/2012 10:48:54 AM : Outperform Start Price: $29.75 GHDX Score: +18.44

Based on speculative takeover potential as Big Pharma looks to fight off the growing patent cliff.

Recs

0
Member Avatar CatFoodMoney (88.42) Submitted: 2/24/2012 12:52:11 AM : Outperform Start Price: $28.51 GHDX Score: +24.75

Winning!

Recs

2
Member Avatar nilamr (44.12) Submitted: 8/1/2010 2:33:15 PM : Outperform Start Price: $13.00 GHDX Score: +147.89

Good mgmt, mgmt have skin in the game, growing field, great execution in building payment from insurance companies.

Recs

0
Member Avatar BossMan2010 (24.60) Submitted: 6/15/2010 6:59:21 PM : Outperform Start Price: $14.38 GHDX Score: +121.77

A whole new way to diagnose that has to catch on. With limited competition, this company will do well.

Recs

1
Member Avatar gt1135 (49.63) Submitted: 2/10/2010 9:49:51 AM : Outperform Start Price: $16.95 GHDX Score: +80.69

Sitting near 52 week low. It won't last. Wish I had more real $$ to invest in this one at the moment.

Recs

1
Member Avatar simonhs (< 20) Submitted: 2/9/2010 7:28:05 PM : Outperform Start Price: $17.09 GHDX Score: +78.82

Aging population, more and more cancer. Might as well make some money off it.

Recs

1
Member Avatar scoobamang (< 20) Submitted: 11/25/2009 10:52:00 PM : Outperform Start Price: $18.80 GHDX Score: +61.97

Revenue increasing at a very nice clip, about to climb out of the red and into profitability, nice cash cushion. Life science sounds sexy.

Recs

1
Member Avatar neilphipps (< 20) Submitted: 6/23/2009 4:31:02 PM : Outperform Start Price: $16.48 GHDX Score: +61.77

Genomics is a promising direction for genetic studies.

Recs

1
Member Avatar Cab53RobertMsnG (63.69) Submitted: 5/28/2009 2:12:13 PM : Outperform Start Price: $19.05 GHDX Score: +34.49

GHDX

Recs

1
Member Avatar jajex1 (98.13) Submitted: 5/12/2009 9:52:38 AM : Outperform Start Price: $19.66 GHDX Score: +29.19

fransgeraedts pick

Recs

4
Member Avatar zzlangerhans (99.67) Submitted: 5/10/2009 6:33:47 PM : Outperform Start Price: $20.17 GHDX Score: +26.45

Oncotype DX revenues for the last four quarters were 26, 28, 31 and 34 million respectively. The assay was also recently shown to be predictive of distant recurrence in colon cancer, although the market was apparently disappointed by its inability to predict the effectiveness of chemotherapy as it does in breast cancer. The company remains unprofitable as they aggressively pursue expanded indications for the Oncotype DX assay, but the burn rate is well controlled with a cash position that will carry them safely at least through the end of 2010 without dilution. Due to their reliance on a single product and lack of a clear pipeline, GH has an inherently weaker risk/reward profile when compared to Myriad. However, their current share price represents an attractive entry point given that they were at 27 a month ago without any change in fundamentals.

Recs

1
Member Avatar SmallPimpin (94.30) Submitted: 5/6/2009 8:14:03 PM : Outperform Start Price: $19.60 GHDX Score: +32.81

Mmm...medical tests...

Recs

1
Member Avatar jdwoollard (< 20) Submitted: 10/13/2008 6:12:51 PM : Outperform Start Price: $21.00 GHDX Score: +35.13

This company allows for targeted treatment of breast cancer. By better determining patients that will benefit from chemotherapy, there are substantial benefits for the patient and for the payors.

Recs

3
Member Avatar WindRules (< 20) Submitted: 8/16/2008 2:32:28 PM : Outperform Start Price: $23.97 GHDX Score: +39.67

This spring they got clinical validation, they received insurance approval for the Oncotype Dx test for estrogen receptor positive breast cancer. They test the DNA of the tumor against the DNA of the person who had the tumor and this gives a personalized predictor of the odds of that same cancer recurring in that person. They also test chemo therapies against and make recommendations. This is far better than population statistics, and the fact that they have insurance approval for the test means increased income. I gather that the test for progesterone receptor positive tumors is close to approval.

I spoke to a member of the board of trustees of BC/BS and he was pleased that it had been used on me. This was within 3 months of approval. It has saved me from months of chemo and radiation. It saves the insurance companies all of that money that would have been spent on my care.

With a PE ratio of 2.83, this seems a go to me.

Recs

1
Member Avatar surehand123 (83.64) Submitted: 8/8/2008 12:03:33 AM : Outperform Start Price: $22.53 GHDX Score: +45.70

Q2 revenue grew 81%, beat the estimates by .03 cents, ripe for acquisition.

Recs

1
Member Avatar NWTOGME (< 20) Submitted: 6/16/2008 8:29:49 PM : Outperform Start Price: $21.04 GHDX Score: +64.21

Showing earnings improvment, GHDX looks like there in bargain box.

Recs

2
Member Avatar oncqueen (69.98) Submitted: 12/19/2007 6:22:23 PM : Outperform Start Price: $19.34 GHDX Score: +87.90

The Oncotype Dx test divides tumors that APPEAR likely to do well with hormonal therapy (non-chemo) from those that are "wolves in sheep's clothing," tame-appearing tumors that really need chemo to be cured. It is the fear of the latter, however uncommon, that makes oncologists give chemo to so very many young and young-ish patients "just to be safe."
The test is expensive but a drop in the bucket compared to chemo, so more and more insurance companies are covering it, and I think there is reason to expect that the indications will expand in the future, so what we may be seeing now is "the tip of the iceberg"---of cash, that is.

Recs

1
Member Avatar quotean (53.62) Submitted: 10/23/2007 3:05:35 PM : Outperform Start Price: $24.08 GHDX Score: +52.02

Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer in the United States

Recs

1
Member Avatar Randomchaos (46.33) Submitted: 10/13/2007 5:19:52 AM : Outperform Start Price: $19.86 GHDX Score: +84.50

God bless it all! I actually bought this stock when it was in the $9+. Had to sell it but hate myself for it.

Recs

1
Member Avatar davetrader20xx (22.79) Submitted: 9/26/2007 10:08:12 AM : Outperform Start Price: $19.46 GHDX Score: +86.59

Genomics will become much more prevalent in the future as people move on to the next frontier, biology.

Results 1 - 20 of 36 : 1 2 Next »

Featured Broker Partners


Advertisement